AKBA today
$0.47-$0.02 (-4.78%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns up above $0.80
Key levels
Resistance$0.80
Resistance$0.54
Support$0.45
Support$0.36
Latest news & SEC filings
AnalystHC Wainwright keeps Buy rating on Akebia Therapeutics, cuts price target
AnalystHC Wainwright keeps Buy rating on Akebia Therapeutics, cuts target to $4
AnalystBTIG keeps Buy rating on Akebia Therapeutics, cuts price target to $3
All AKBA news →About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on kidney disease. It sells two oral medicines in the U.S.: Vafseo (vadadustat) for anemia in adult dialysis patients with chronic kidney disease, and Auryxia (ferric citrate) for phosphorus control in dialysis patients and iron deficiency anemia in non-dialysis patients. Vafseo is also approved and marketed by partners in other countries. Its pipeline includes treatments in development for rare kidney diseases such as FSGS, IgA nephropathy, C3 glomerulopathy, and lupus nephritis.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
Akebia Therapeutics, Inc. (AKBA)
What Is the Price Target for AKBA?
SEPT Low Target
$1.00
SEPT Mid Target
$4.00
SEPT High Target
$4.50
Analyst Consensus
$4.00
Is AKBA a Buy or Sell Right Now?
Thesis
- •Revenue growing 47.5% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AKBA.
Start Free Trial →Is AKBA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$3.06
17
Moat Score
NONE
5/9
Piotroski Score
-4.8
Altman Z-Score
What Is Smart Money Doing with AKBA?
Insider Signal
SELLING
1 buys / 15 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AKBA Growth Story
Revenue YoY
47.5%
3yr Revenue CAGR
-6.9%
EPS Growth YoY
93.94%
FCF Growth YoY
266.4%
Revenue Trend
ACCELERATING
Dark Pool Trades for AKBA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AKBA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 16:24:55 | $0.48 | 2,000 | $$956 | SELL |
| 16:24:50 | $0.48 | 9,000 | $$4K | SELL |
| 16:24:49 | $0.48 | 1,100 | $$527 | MIDPOINT |
| 16:24:49 | $0.48 | 1,100 | $$527 | MIDPOINT |
| 16:24:49 | $0.48 | 1,400 | $$671 | MIDPOINT |
5 dark pool trades shown · $$7K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Akebia Therapeutics, Inc. (AKBA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AKBA — frequently asked questions
What is AKBA stock price today?
Akebia Therapeutics, Inc. (AKBA) is at $0.47, down 4.78% (-$0.02) at the Nov 13, 2026 close.
Why is AKBA stock moving today?
Latest AKBA news — Nov 7, 2026: HC Wainwright keeps Buy rating on Akebia Therapeutics, cuts price target · Nov 6, 2026: HC Wainwright keeps Buy rating on Akebia Therapeutics, cuts target to $4
What is the AKBA price target?
The average analyst price target for AKBA is $4.00, ranging from $1 to $5, based on 3 analysts.
What do analysts rate AKBA?
Analyst ratings for AKBA: 0 Buy, 4 Hold, 1 Sell — consensus Hold.
Did AKBA beat earnings?
AKBA last reported on Aug 5, 2026: EPS -$0.02 vs -$0.04 expected — a beat of 52.4%.
Does AKBA pay a dividend?
AKBA does not currently pay a dividend.
How much debt does AKBA have?
Akebia Therapeutics, Inc. reported $50M of debt and $156M of cash (Jun 30, 2026).
What are AKBA support and resistance levels?
Support: $0.45, $0.36, $0.24. Resistance: $0.54, $0.80, $0.92.
What are insiders doing with AKBA?
Insider activity: SELLING, 1 buys and 15 sells in the last 90 days.
What is the latest news on AKBA?
Nov 7, 2026: HC Wainwright keeps Buy rating on Akebia Therapeutics, cuts price target · Nov 6, 2026: HC Wainwright keeps Buy rating on Akebia Therapeutics, cuts target to $4 · Nov 5, 2026: BTIG keeps Buy rating on Akebia Therapeutics, cuts price target to $3